#healthcare-policy

Biopharma companies are restructuring international licensing agreements to reduce their exposure to Most Favored Nation pricing rules, which link US drug prices to the lowest prices paid in other countries.

The Centers for Medicare and Medicaid Services' innovation arm is more than doubling its staff to develop pilot programs that reduce drug costs across Medicare and Medicaid, signaling aggressive federal action on pharmaceutical pricing.

The FDA unveils a new retention bonus program aimed at keeping experienced drug reviewers as the agency faces mounting workforce challenges.

New Medicaid work mandates taking effect in 2027 could strip health coverage from nearly 8 million unpaid caregivers who provide an estimated $600 billion in annual care, pushing families into impossible choices between employment and looking after loved ones.